BR0116658A - Preparação farmacêutica contendo ciclodextrina - Google Patents

Preparação farmacêutica contendo ciclodextrina

Info

Publication number
BR0116658A
BR0116658A BR0116658-1A BR0116658A BR0116658A BR 0116658 A BR0116658 A BR 0116658A BR 0116658 A BR0116658 A BR 0116658A BR 0116658 A BR0116658 A BR 0116658A
Authority
BR
Brazil
Prior art keywords
cyclodextrin
ebselene
aqueous solution
aqueous
dissolving
Prior art date
Application number
BR0116658-1A
Other languages
English (en)
Inventor
Norio Suzuki
Yukihiko Nagase
Hitoshi Yamauchi
Original Assignee
Daiichi Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Seiyaku Co filed Critical Daiichi Seiyaku Co
Publication of BR0116658A publication Critical patent/BR0116658A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
    • C07D293/10—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D293/12—Selenazoles; Hydrogenated selenazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Medical Informatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"PREPARAçãO FARMACêUTICA CONTENDO CI CLODEXTRINA". A presente invenção pode fornecer o seguinte que é uma solução aquosa transparente de uma quantidade suficiente de ebseleno e útil como uma injeção. Uma preparação com base aquosa ou solução aquosa compreendendo ebseleno e ciclodextrina. Uma injeção compreendendo a solução aquosa. Uma infusão gotejante intravenosa compreendendo a solução aquosa. Um processo para a produção de uma solução aquosa contendo ebseleno e ciclodextrina, que compreende a dissolução de ebseleno em um solvente orgânico miscível na água enquanto dissolve separadamente uma ciclodextrina em um solvente aquoso, misturando ambas as soluções, então secando a mistura, e misturando o produto seco resultante com um solvente aquoso. Uma preparação seca compreendendo ebseleno e ciclodextrina. Um processo para a produção de uma solução contendo ebseleno e ciclodextrina, que compreende a dissolução de ebseleno em um solvente orgânico miscível na água enquanto dissolve separadamente a ciclodextrina em um solvente aquoso, e mistura ambas as soluções.
BR0116658-1A 2001-01-04 2001-12-17 Preparação farmacêutica contendo ciclodextrina BR0116658A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001000247 2001-01-04
JP2001016022 2001-01-24
PCT/JP2001/011048 WO2002055076A1 (fr) 2001-01-04 2001-12-17 Preparation pharmaceutique contenant de la cyclodextrine

Publications (1)

Publication Number Publication Date
BR0116658A true BR0116658A (pt) 2003-12-30

Family

ID=26607336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116658-1A BR0116658A (pt) 2001-01-04 2001-12-17 Preparação farmacêutica contendo ciclodextrina

Country Status (12)

Country Link
US (1) US20040053888A1 (pt)
EP (1) EP1348432A4 (pt)
JP (1) JPWO2002055076A1 (pt)
KR (1) KR20030068203A (pt)
CN (1) CN1492760A (pt)
AR (1) AR032386A1 (pt)
BR (1) BR0116658A (pt)
CA (1) CA2434077A1 (pt)
MX (1) MXPA03006071A (pt)
NO (1) NO20033042L (pt)
RU (1) RU2003119972A (pt)
WO (1) WO2002055076A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2368484A1 (en) 1999-03-31 2000-10-05 Daiichi Pharmaceutical Co., Ltd. Substrates for thioredoxin reductase
CN1853627B (zh) * 2005-04-25 2011-08-10 曾慧慧 双苯并异硒唑乙烷环糊精或环糊精衍生物包合物及其制备方法和其用途
SG164368A1 (en) 2005-07-18 2010-09-29 Bipar Sciences Inc Treatment of cancer
JP4886233B2 (ja) * 2005-07-21 2012-02-29 独立行政法人物質・材料研究機構 エブセレンの可溶化方法
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
EP1795183B1 (en) * 2005-12-09 2009-07-15 Teva Pharmaceutical Industries, Inc. Aqueous dispersions and solutions of difficult to dissolve compounds and methods of their preparation
US20100160442A1 (en) * 2006-07-18 2010-06-24 Ossovskaya Valeria S Formulations for cancer treatment
WO2008030891A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof
CA2662517A1 (en) 2006-09-05 2008-03-13 Jerome Moore Treatment of cancer
CN100486645C (zh) * 2006-09-12 2009-05-13 南京师范大学 含有环糊精紫杉醇包合物的药物组合物及其制备方法
CN100411688C (zh) * 2006-09-12 2008-08-20 南京师范大学 含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
NZ579098A (en) * 2007-01-16 2012-07-27 Bipar Sciences Inc Formulations for cancer treatment
US7732491B2 (en) 2007-11-12 2010-06-08 Bipar Sciences, Inc. Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents
AU2010210636A1 (en) * 2009-02-04 2011-09-22 Bipar Sciences, Inc. Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor
GB201102248D0 (en) 2011-02-09 2011-03-23 Isis Innovation Treatment of bipolar disorder
RU2451680C1 (ru) * 2011-02-21 2012-05-27 Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство
WO2015042170A1 (en) 2013-09-17 2015-03-26 Wayne State University Compositions and uses of combinations of dim-related indoles and selected anti-androgen compounds
WO2015071841A1 (en) 2013-11-12 2015-05-21 Druggability Technologies Holdings Limited Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10058542B1 (en) 2014-09-12 2018-08-28 Thioredoxin Systems Ab Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
US10576086B2 (en) 2015-06-12 2020-03-03 University Of Greenwich Triazine derivatives as interferon-gamma inhibitors
TWI830180B (zh) * 2017-06-30 2024-01-21 財團法人工業技術研究院 化合物之液體劑型的醫藥配方
WO2021054863A1 (ru) * 2019-09-18 2021-03-25 Рахимджан Ахметджанович РОЗИЕВ Стимулятор процессов репаративной регенерации тестикулярной ткани
WO2023240094A1 (en) * 2022-06-06 2023-12-14 Sound Pharmaceuticals Inc. Amorphous dosage form containing ebselen
WO2024181358A1 (ja) * 2023-02-27 2024-09-06 国立大学法人東北大学 医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01131113A (ja) * 1987-08-27 1989-05-24 Dai Ichi Seiyaku Co Ltd 脳障害治療剤
US5288734A (en) * 1988-10-29 1994-02-22 A. Nattermann & Cie Gmbh Stable parenteral solution of 2-phenyl-1.2-benzisoselenazol-3(2H)-one and process for producing the same
AU5780696A (en) * 1995-06-02 1996-12-18 Takeda Chemical Industries Ltd. Stabilized composition comprising an antiulcerative benzimid azole
US6596706B1 (en) * 1997-11-07 2003-07-22 Daiichi Pharmaceutical Co., Ltd. Piperazine-cyclodextrin complexes
AU1411600A (en) * 1998-11-30 2000-06-19 Sankyo Company Limited Immunoglobulin preparations

Also Published As

Publication number Publication date
NO20033042L (no) 2003-09-04
EP1348432A4 (en) 2005-08-10
RU2003119972A (ru) 2004-12-27
CA2434077A1 (en) 2002-07-18
WO2002055076A1 (fr) 2002-07-18
JPWO2002055076A1 (ja) 2004-05-13
NO20033042D0 (no) 2003-07-02
KR20030068203A (ko) 2003-08-19
AR032386A1 (es) 2003-11-05
US20040053888A1 (en) 2004-03-18
MXPA03006071A (es) 2004-02-26
EP1348432A1 (en) 2003-10-01
CN1492760A (zh) 2004-04-28

Similar Documents

Publication Publication Date Title
BR0116658A (pt) Preparação farmacêutica contendo ciclodextrina
BR0215331A (pt) Composições aquosas contendo metronidazol
BR0104287A (pt) Composição, e, processo para preparação da composição de um ciclopropeno encapsulado
BR0103844A (pt) Sistema de aditivo polimérico múltiplo, processo para produzir o mesmo, composição polimérica, e, processo para produzir a mesma
BR0109449A (pt) Processo de reciclagem de um material plástico
BRPI0410772A (pt) tratamento de resinas para diminuir os nìveis de espécies produtoras de cpd e melhorar a estabilidade de gelação
BR0111054A (pt) Microesferas e processo de preparação das mesmas
BRPI0613570A8 (pt) composto ou um sal do mesmo, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, método para tratar doenças mediadas por glk, e, processo para a preparação de um composto.
BRPI0516772A (pt) formulação sólida com solubilidade e estabilidade melhoradas e método para produção da referida formulação
BR9812665A (pt) Agente alvejante
EA200500181A1 (ru) Композиции и способы обработки подземных пород
BR9802439A (pt) Compostos de bispirazolaza, processo para sua preparação e tinturas capilares contendo esses compostos.
BRPI0806318B8 (pt) sacarídeo capsular modificado, processo para modificar um sacarídeo, conjugado proteína sacarídea, molécula e composição farmacêutica
BR0005488A (pt) Processo para a preparação de carbonato de vinileno, e o uso do mesmo
BR0309340A (pt) Materiais, sua preparação e uso
PT1158962E (pt) Processo para a preparacao de formas de dosagem solidas que contem ciclodextrina
BR9904934A (pt) Sistema de descoloração e extração de corante, e, processo para a extração de um corante de matrizes de fibra orgânica e decoloração do corante
AR072359A1 (es) Encapsulacion de agentes biologicamente activos
BRPI0509482A (pt) complexo compreendendo piroxicam, uma ciclodextrina e a arginina, processo de preparação de um complexo, composição farmacêutica, processo de preparação de um composto de inclusão solúvel, e composto de inclusão solúvel
BR0309803A (pt) Composição aquosa de tratamento de metal
AR029385A1 (es) Conjugados y procedimientos para su preparacion asi como su empleo para el transporte de moleculas arilo a traves de membranas biologicas, medicamento, procedimiento para su preparacion, medios de diagnostico y equipo de ensayo.
BR0309625A (pt) Sistema de cristalização que utiliza atomização
PE20030389A1 (es) PROCEDIMIENTO DE PREPARACION DE DERIVADOS 4,4'-DICETO-ß-CAROTENO
BR9917396A (pt) Processo para a deformação permanente de fibras e agentes queratìnicos
BRPI0410958B8 (pt) composição aquosa agroquímica

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]